Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.61 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179470 | 0.86 | AR (0.63) | ARSLC22A12TRPV4 | |
| SCHEMBL23409847 | 0.79 | MRGPRX4 (0.47) | ARSLC22A12TRPV4KIF11 | |
| SCHEMBL29788295 | 0.79 | MRGPRX4 (0.47) | ARSLC22A12TRPV4KIF11 | |
| SCHEMBL9460920 | 0.78 | AR (0.56) | ARSLC22A12 | |
| SCHEMBL14861411 | 0.77 | AR (0.71) | AR | |
| SCHEMBL22342512 | 0.76 | AR (1.00) | AR | |
| SCHEMBL472402 | 0.74 | TRPV4 (0.53) | ARSLC22A12TRPV4KIF11 | |
| SCHEMBL30899301 | 0.74 | TRPV4 (0.53) | ARSLC22A12TRPV4KIF11 | |
| SCHEMBL3571001 | 0.73 | AR (0.47) | ARTRPV4KIF11 | |
| SCHEMBL14570876 | 0.73 | MRGPRX4 (0.49) | ARKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100469769-C | Benzyl-pyridazinons as reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (CH) | 2009-03-18 | — | — | CN | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | AR 2411/4885SLC22A12 2830/4885TRPV4 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.